Sophia Genetics Sa · NASDAQ:SOPH
Sophia Genetics Sa — Q3 2024 Earnings Presentation
24 slides from Sophia Genetics Sa's earnings presentation, Nov 5, 2024
Slide 1: Investor Presentation
Investor Presentation November 5th, 2024
Slide 2: Cautionary notices
Cautionary notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, pro
Slide 3: SOPHiA GENETICS at-a-glance
SOPHiA GENETICS at-a-glance 2024 70+ 780+ 1.8 Million+ 697 scientific 740 publications (as of Oct 2024) 3 © SOPHiA GENETICS 2024 (1) Data as of September 30, 2024.
Slide 4: Data-driven medicine is transforming patient care
Data-driven medicine is transforming patient care © SOPHiA GENETICS 2024
Slide 5: SOPHiA DDM is a decentralized analytics platform
SOPHiA DDMTM is a decentralized analytics platform which computes complex data and provides insights to Clinical and BioPharma customers 5 © SOPHiA GENETICS 2024
Slide 6: The total addressable market for SOPHiA GENETICS is sizeable
The total addressable market for SOPHiA GENETICS is sizeable Clinical market BioPharma market Generating insights from multimodal data Generating insights from multimodal data to help Clinicians with screening, early detection, to help BioPharma companies with drug diagnosis, therapy selection, and
Slide 7: The SOPHiA DDM Platform uniquely serves this market
The SOPHIA DDMTM Platform uniquely serves this market 7 © SOPHiA GENETICS 2024 (1) NPS Score reflects survey results users of SOPHiA DDMTM ’s core genomic module (i.e., SOPHiA DDM for Genomics) only and excludes survey results from users of add-on modules such as Alamut.
Slide 8: Industry-leading multimodal capabilities driven by AI
Industry-leading multimodal capabilities driven by AI makes SOPHiA DDMTM the platform of choice for actionable patient insights 8 © SOPHiA GENETICS 2024
Slide 9: Comprehensive portfolio of SOPHiA DDM applications for cancer and rare diseases
Our comprehensive portfolio of SOPHiA DDMTM applications addresses the burden of cancer and rare diseases 9 © SOPHiA GENETICS 2024
Slide 10: Enabling healthcare institutions to become beacons of precision medicine
Enabling healthcare institutions to become beacons of precision medicine Business model for Clinical market ILLUSTRATIVE GENOMIC OFFERING Consumption-based business model charges customers per analysis run on SOPHiA DDMTM 10 © SOPHiA GENETICS 2024
Slide 11: Our vast, global network uses SOPHiA DDM daily
Our vast, global network use SOPHiA DDMTM daily and contribute to a collective intelligence (1) Represents active customers who have generated revenue through the SOPHiA DDMTM Platform usage or Alamut licenses as of September 30, 2024. 11 © SOPHiA GENETICS 2024
Slide 12: Delivering valuable insights to BioPharma across the drug continuum
Delivering valuable insights to BioPharma across the drug continuum Business model for BioPharma market SOPHiA DDM™ DATA ANALYTICS 1.8M+ genomic profiles + Multimodal dataset Ai Factories SOPHiA DDM™ DIAGNOSTICS Global network 780+ institutions 70+ countries 12 © SOPHiA GENETICS 2024 * The developed
Slide 13: SOPHiA DDM creates flywheel effects from serving both markets
SOPHiA DDMTM creates flywheel effects from serving both markets 13 © SOPHiA GENETICS 2024
Slide 14: Analysis volume on SOPHiA DDM is growing rapidly
Analysis volume on SOPHiA DDMTM is growing rapidly across all applications 362% 32% 26% 25% 19% 14 © SOPHiA GENETICS 2024 (1) Year-over-year analysis volume as of December 31, 2023. Analysis volume growth is presented excluding COVID-related volumes.
Slide 15: Data processed on SOPHiA DDM has exploded over the years
Data processed on SOPHiA DDMTM has exploded over the years 15 © SOPHiA GENETICS 2024 (1) Figures represent an estimate of total data processed on SOPHiA DDMTM as of December 31, 2023.
Slide 16: Q3 2024 Highlights
Q3 2024 Highlights Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% Expanding usage of SOPHiA DDM™ worldwide Revenue $15.9 million • 462 core genomics customers as of September 30, 2024, up from 431 in Q3 2023 vs. $16.3M in Q3 2023 • Continued executing our land and
Slide 17: Near-term catalysts offer exciting opportunities for growth
Near-term catalysts offer exciting opportunities for growth Potential growth drivers New applications Launch and deploy new offerings in Liquid Biopsy, Solid Tumors, Whole Genome Sequencing, MRD, and multimodal analytics U.S. market Continue expanding in the U.S. market and build off 70% y/y revenue
Slide 18: 2024 annual guidance
2024 annual guidance FY 2023 FY 2024 YoY Category Key drivers results Guide improvement • Focus on accelerating new customers into routine usage faster • Capitalize on growing demand for Liquid Biopsy application, MSK- 4% – 7% ACCESS® powered with SOPHiA DDMTM Revenue $62.4M $65M - $67M growth • Mai
Slide 19: SOPHiA GENETICS is on a path to profitability in the next 2 years
SOPHiA GENETICS is on a path to profitability in the next 2 years Q3 2024 marked another period of strong cost management 73.1% Adj. gross margin vs. 72.5% in Q3 2023 (2) 10.4% Adj. operating loss improvement (3) Improved adjusted operating loss by 10% to $10.6M in Q3 $95.8M 2024 vs $11.8M in Q3 202
Slide 20: Delivering value to patients and shareholders
Delivering value to patients and shareholders Sizable addressable ~$40B market market opportunity(1) Market-leading $400M+ 740 technology invested since scientific inception publications FY 2023 highlights Customers love Figures as of Dec 31, 2023 75 ~4% +87 NPS score among annualized new customers
Slide 21: Democratizing Data-Driven Medicine, Together
+ oo ' *. SOPHIA * ee GENETICS” Democratizing Data-Driven Medicine, Together
Slide 22: Financial overview
Financial overview ($ in millions, except for margin data) Q3 2024 P&L Q3 2024 Q3 2023 Change Y/Y Total revenues $15.9 $16.3 (2.8%) Adjusted gross margin %(1) 73.1% 72.5% +61bps Adjusted operating loss(2) ($10.6) ($11.8) 10.4% Cash burn(3) ($9.6) ($15.8) (39.1%) Balance sheet September 30, 2024 Sept
Slide 23: Reconciliation of IFRS Financials to Adjusted Financials
Reconciliation of IFRS Financials to Adjusted Financials 2023 2024 (Amounts in USD Thousands) Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY IFRS Revenue $13,966 $15,054 $16,303 $17,048 $62,371 $15,779 $15,808 $15,853 Gross Profit $9,694 $10,047 $11,273 11,898 $42,913 $10,405 $10,776 $10,654 Gross Margin 69% 67% 69%
Slide 24: Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth Excluding COVID-19
Reconciliation of IFRS Revenue Growth to Constant Current Revenue Growth Excluding COVID-19-Related Revenue (Amounts in USD Thousands) Q3 2023 FY 2023 Q3 2024 Y-o-Y Growth IFRS Revenue $16,303 $62,371 $15,853 (3%) Current Period Constant Currency Impact (1) — — (58) Constant Currency Revenue $16,303